Risk Factors for the Development of Choroidal Neovascularization in the Fellow Eye of Patients with Age Related Macular Degeneration – A Three Year Follow-up Study.

Risk Factors for the Development of Choroidal Neovascularization in the Fellow Eye of Patients with Age Related Macular Degeneration – A Three Year Follow-up Study.

Risk Factors for the Development of Choroidal Neovascularization in the Fellow Eye of Patients with Age Related Macular Degeneration – A Three Year Follow-up Study.

Santos A.R., Cachulo M.L., Fonseca P., Nunes S., Bernardes R., Cunha-Vaz J., Silva R.

Invest Ophthalmol Vis Sci 2011;52: 1774.

2011

Noninvasive Assessment of Blood-Retinal Barrier Function by High-Definition Optical Coherence Tomography.

Noninvasive Assessment of Blood-Retinal Barrier Function by High-Definition Optical Coherence Tomography.

Noninvasive Assessment of Blood-Retinal Barrier Function by High-Definition Optical Coherence Tomography.

Santos T., Bernardes R., Santos A., Cunha-Vaz J.

In: Technologies and Medical Sciences. RM Natal Jorge, João Manuel RS Tavares, Marcos Pinotti, Alan Peter Slade, Eds. The Netherlands: CRC Press. 2011, 215-219.

2011

Poor Correlation Between PHP Measurements and Development of Choroidal Neovascularization in AMD Patients.

Poor Correlation Between PHP Measurements and Development of Choroidal Neovascularization in AMD Patients.

Poor Correlation Between PHP Measurements and Development of Choroidal Neovascularization in AMD Patients.

Santos T., Santos A., Bernardes R., Cunha-Vaz J.

Invest Ophthalmol Vis Sci 2011;52: 1053.

2011

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J.F., Schlingemann R.O., Axer-Siegel R., Wiedemann P., Simader C., Gekkieva M., Weichselberger A.; EXCITE Study Group

Ophthalmology. 2011;118(5):831-9.

2011

Validation of Retmarker AMD for Quantification of Early Age-Related Maculopathy Features.

Validation of Retmarker AMD for Quantification of Early Age-Related Maculopathy Features.

Validation of Retmarker AMD for Quantification of Early Age-Related Maculopathy Features.

Simao S.N., Nunes S., Vilhena N., Cachulo M.L., Faria de Abreu J., Cunha-Vaz J., Silva R.

Invest Ophthalmol Vis Sci 2011;52: 94.

2011

A Phase 2/3, Multicentre, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema.

A Phase 2/3, Multicentre, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema.

A Phase 2/3, Multicentre, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema.

Sultan M., Zhou D., Loftus J. et al, for the Macugen 1013 Study Group.

Ophthalmology 2011;118:1107-1118.

2011